A team from the University Medical Centre Groningen (NL) has used multiple Olink® Target 96 panels to identify proteins associated with metabolic syndrome (MetS) symptoms in heart failure (HF) patients. Patients with MetS are twice as likely to develop HF and adverse progression of MetS significantly influences the therapeutic management of HF, but the role of MetS in the pathophysiology of HF is poorly understood.
363 unique proteins were measured to compare HF patients with and without MetS in a discovery cohort of 1103 HF patients (42% with MetS) and a validation cohort of 1433 HF patients (43% with MetS). MetS was defined as the presence of at least three of five criteria: central obesity, elevated serum triglycerides, reduced high-density lipoprotein cholesterol, insulin resistance and hypertension. 48 proteins were differentially expressed between MetS +/- HF subjects (43 were elevated, 5 decreased) in patients with metabolic syndrome, while in the validation cohort, 58 were elevated and 3
decreased. A total of 29 biomarkers were found to be elevated in both the discovery and validation cohorts. The most significantly elevated biomarkers in patients with metabolic syndrome from both cohorts were LEP, FABP4, IL1RN, TNFRSF11A & RET.
They then applied pathway analysis to these results, identifying 10 enriched pathways in the discovery cohort and 6 in the validation cohort, all of which were related to inflammation. One specific inflammatory pathway that was common to both cohorts was up-regulation of the natural killer cell-mediated cytotoxicity pathway. Combined with additional clinical data, the results suggest that MetS in HF is associated with biomarkers and pathways relating to obesity, lipid metabolism and immune responses underlying chronic inflammation.
van der Hoef CCS, Boorsma EM, Emmens JE, et al. Biomarker signature and pathophysiological pathways in chronic heart failure patients with metabolic syndrome. (2023) European Journal of Heart Failure, DOI: 10.1002/ejhf.2760
Metabolic syndrome is prevalent in patients with heart failure and associated with increased concentration of biomarkers and activation of pathways related to lipid metabolism, obesity, and immune responses associated with chronic inflammation
van der Hoef et al. (2023)
Peer-reviewed publications citing the use of Olink panels
Olink’s Proximity Extension Assay (PEA) technology has been used for protein biomarker discovery and analysis across a very broad range of disease areas and applications, providing actionable insights into disease biology and helping to drive future development of new and better therapeutics. There are now well over 1000 publications citing the use of our assays and the list is growing rapidly. Please visit our library of publications to see some of the extraordinary work produced by Olink customers.